06 maggio 2021 12:51
Fonte: Adnkronos
#salute-e-benessere
- Roche and Lilly will integrate data from Lilly s connected insulin pen solution into the mySugr app in several countries.
- Both companies are dedicated to driving new possibilities to ease the complexity of daily decision making for people with diabetes on insulin pen therapy and their healthcare professionals.
- By collaborating with Lilly, Roche accelerates growth of its open ecosystem enabling its strategy of integrated Personalised Diabetes Management (iPDM).
BASEL, Switzerland, May 6, 2021 /PRNewswire/ Roche today announced that it has signed a collaboration agreement with Eli Lilly and Company, a global leader in diabetes care delivering innovative solutions including medicines and technologies, to work towards optimising the management of insulin pen therapy. By collaborating with Lilly, Roche follows its ambition to create an open ecosystem including its own and partner devices, solutions and services, a
CET- Comunicado - ;ultimaHoraHtml += + json.lead + ;}ultimaHoraHtml += ; document.getElementById( urgente ).innerHTML = ultimaHoraHtml; } } }); The partnership will create new opportunities to lower the burden for people with diabetes in daily therapy management and to improve therapy outcomes(1). By partnering with Diabeloop, Roche steps into the field of automated insulin delivery (AID) representing a milestone in Roche s strategy of integrated Personalised Diabetes Management (iPDM).
BASEL, Dec. 11, 2020 /PRNewswire/ Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it is partnering with the French MedTech company Diabeloop to advance the management of insulin pump therapy, creating new opportunities to lower the burden of constant insulin dose adjustment for people with diabetes and to improve therapy outcomes(1). The partnership marks Roche s first step in the field o